No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury

Chem Res Toxicol. 2016 Dec 19;29(12):2111-2113. doi: 10.1021/acs.chemrestox.6b00400. Epub 2016 Nov 18.

Abstract

It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells. However, analysis of PBMC and cloned T-cells from patients with HLA-DRB1*07:01-restricted lapatinib-induced liver injury revealed no evidence for drug-specific activation. T cells were exposed to lapatinib, the M11 aldehyde, and quinone imine [oxidized form of hydroquinone amine M1] metabolites. Reactivity of the quinone imine was confirmed by mass spectrometry.

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Chemical and Drug Induced Liver Injury / blood
  • Chemical and Drug Induced Liver Injury / immunology*
  • HLA-DRB1 Chains / genetics*
  • Humans
  • Lapatinib
  • Lymphocyte Activation / drug effects*
  • Quinazolines / adverse effects*
  • Quinazolines / pharmacology
  • T-Lymphocytes / drug effects*

Substances

  • Antineoplastic Agents
  • HLA-DRB1 Chains
  • Quinazolines
  • Lapatinib